Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Download Documentation Jefferies 2015 Global Healthcare Conference
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$35.59
Change (%) Stock is Down 0.24 (0.67%)
Volume512,209
Data as of 04/29/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
04/26/16The Medicines Company to Announce First Quarter Financial Results on May 9, 2016
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 26, 2016-- The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for May 9th at 8:30 a.m. Eastern Time to discuss first quarter financial results and operational developments. The conference call will be available via phone and webcast. The dial-in information is listed below: Domestic Dial In: + 1 (877) 359-9508 International Dial In: + 1 (224) 357-23... 
Printer Friendly Version
04/11/16FDA Grants Fast Track Status for Investigational Antibiotic CARBAVANCE® (meropenem-vaborbactam)
TANGO Phase 3 Clinical Trials Underway for cUTI and Serious Bacterial Infections Due to Confirmed or Suspected Carbapenem-resistant Enterobacteriaceae (CRE) PARSIPPANY, N.J. --(BUSINESS WIRE)--Apr. 11, 2016-- The Medicines Company (NASDAQ:MDCO) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Designation to the investigational agent CARBAVANCE® (meropenem-vaborbactam) for the treatment of complicated ur... 
Printer Friendly Version
04/04/16The Medicines Company Announces Participation at 2016 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held April 9-12 in Amsterdam
Researchers to present data on the activity of the investigational agent CARBAVANCE® (meropenem-vaborbactam) against newly discovered carbapenemases, and ORBACTIV® (oritavancin) against European clinical isolates of gram-positive bacteria, including those resistant to other drugs. PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 4, 2016-- The Medicines Company (NASDAQ:MDCO) today announced that investigators will presen... 
Printer Friendly Version
03/28/16The Medicines Company Announces Participation at 2016 American College of Cardiology (ACC) Scientific Sessions in Chicago
- Researchers to present new analyses highlighting the potential clinical and economic value of KENGREAL® in high risk PCI PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 28, 2016-- The Medicines Company (NASDAQ:MDCO) today announced that investigators will present new analyses from high-risk percutaneous coronary intervention (PCI) patient subgroups from the CHAMPION PHOENIX study with its antithrombotic agent, KENGREAL® (cangrelor) for Injection at ... 
Printer Friendly Version
Upcoming Events
DateTitle
05/09/16 8:30 a.m. ET
Q1 2016 The Medicines Company Earnings Conference Call

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.